XTL Biopharmaceuticals Ltd. (XTLB)

[iHub News]

XTL Biopharmaceuticals (XTLB) acquisition of Psyga Bio targets psychedelic biotech growth

April 29, 2026 10:47 AM
IH Market News

XTL Biopharmaceuticals (NASDAQ:XTLB) announced an acquisition of Psyga Bio, a move that could reposition the company within the emerging psychedelic therapeutics space. The transaction is notable for investors because it adds a clinical pipeline, manufacturing infrastructure, and exposure to a rapidly evolving regulatory environment.

Key Investor Takeaways

• Acquisition of Psyga Bio gives XTL access to seven Phase 2a clinical programs and GMP-ready manufacturing.





• The deal is equity-based, with Psyga shareholders receiving 40% of XTL post-transaction.





• Additional milestone-based equity incentives could increase dilution depending on execution.





• XTLB gains exposure to psychedelic therapies, including psilocybin and ibogaine.





• The transaction depends on maintaining Nasdaq listing and shareholder approvals.

Press Release Overview

XTL entered into a definitive agreement to acquire 100% of Psyga Bio in exchange for newly issued shares representing 40% of the combined company. No cash consideration will be paid at closing.

Psyga brings a licensed, GMP-ready manufacturing facility capable of producing pharmaceutical-grade psychedelic compounds, including psilocybin and ibogaine. The company also maintains a proprietary library of more than 180 mushroom strains.

The pipeline includes seven approved Phase 2a clinical trials expected to begin enrollment soon, targeting mental health, neurological, and addiction-related conditions.

Psyga shareholders may receive an additional 10% in equity tied to milestones, including clinical trial progress and ibogaine commercialization partnerships.

XTL also secured a $1.5 million private placement to support the transaction.

“We believe Psyga represents the type of transformational transaction capable of repositioning XTL as a leading publicly traded biotechnology platform,” said CEO Noam Brand.

Why This Matters for Investors

The acquisition of Psyga Bio may shift XTL’s strategic focus toward psychedelic therapeutics, a sector gaining regulatory and investor attention.

The addition of clinical-stage assets and manufacturing capabilities could expand XTL’s long-term development pipeline and potential commercialization pathways.

However, the equity-heavy structure introduces dilution risk, particularly with additional milestone-based share issuance.

The transaction also hinges on Nasdaq listing status and regulatory approvals, which introduces execution uncertainty.

What to Watch For Next

• Shareholder approval and regulatory clearance of the transaction





• Progress on Psyga’s Phase 2a clinical trials





• Any partnerships tied to ibogaine or psilocybin programs





• Completion of the $1.5 million private placement





• XTL’s ability to maintain its Nasdaq listing

Conclusion

XTL’s acquisition of Psyga Bio marks a strategic pivot into psychedelic biotechnology, combining clinical assets and manufacturing infrastructure. For investors, the opportunity comes with execution risks tied to clinical progress, dilution, and regulatory dependencies.

XTL Biopharmaceuticals stock price

Original: XTL Biopharmaceuticals (XTLB) acquisition of Psyga Bio targets psychedelic biotech growth